Aduro BioTech, Inc. (Aduro)

Oncology Corporate Profile

HQ Location

626 Bancroft Way, #3C
Berkeley, CA 94710

Company Description

Aduro BioTech, Inc. is a clinical-stage immunotherapy company located in Berkeley, California. Aduro has completed a randomized, controlled Phase 2 clinical trial in patients with metastatic pancreatic cancer and is conducting a Phase 1B trial in patients with malignant pleural mesothelioma. The company's pipeline also includes preclinical programs in glioblastoma, prostate cancer, melanoma, malaria, HBV and tularemia.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
CRS-207 (+ antiPD-1)immunotherapyGastric cancerII
GVAX vaccine / CRS-207immunotherapyMesotheliomaII
CRS-207 (+ Keytruda®)immunotherapyMesotheliomaIIMerck
GVAX vaccine / CRS-207immunotherapyPancreaticII
ADU-623immunotherapyGlioblastoma Multiforme (GBM)I
ADU-741immunotherapyNon Small Cell Lung Cancer (NSCLC)IJanssen
GVAX vaccine / CRS-207immunotherapyOvarian cancerI
CRS-207 (+ antiPD-1)immunotherapyOvarian cancerIIncyte
ADU-741immunotherapyProstate cancerIJanssen
ADU-214immunotherapyNon Small Cell Lung Cancer (NSCLC)Preclinical
ADU-214immunotherapyOvarian cancerPreclinical

View additional information on product candidates here »


Recent News Headlines

There are no news items to display